| Literature DB >> 28905856 |
Xavier Bossuyt1, Jan-Willem Cohen Tervaert2, Yoshihiro Arimura3, Daniel Blockmans4, Luis Felipe Flores-Suárez5, Loïc Guillevin6, Bernhard Hellmich7, David Jayne8, J Charles Jennette9, Cees G M Kallenberg10, Sergey Moiseev11, Pavel Novikov11, Antonella Radice12, Judith Anne Savige13, Renato Alberto Sinico14, Ulrich Specks15, Pieter van Paassen16, Ming-Hui Zhao17, Niels Rasmussen18, Jan Damoiseaux19, Elena Csernok7.
Abstract
Anti-neutrophil cytoplasmic antibodies (ANCAs) are valuable laboratory markers used for the diagnosis of well-defined types of small-vessel vasculitis, including granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA). According to the 1999 international consensus on ANCA testing, indirect immunofluorescence (IIF) should be used to screen for ANCAs, and samples containing ANCAs should then be tested by immunoassays for proteinase 3 (PR3)-ANCAs and myeloperoxidase (MPO)-ANCAs. The distinction between PR3-ANCAs and MPO-ANCAs has important clinical and pathogenic implications. As dependable immunoassays for PR3-ANCAs and MPO-ANCAs have become broadly available, there is increasing international agreement that high-quality immunoassays are the preferred screening method for the diagnosis of ANCA-associated vasculitis. The present Consensus Statement proposes that high-quality immunoassays can be used as the primary screening method for patients suspected of having the ANCA-associated vaculitides GPA and MPA without the categorical need for IIF, and presents and discusses evidence to support this recommendation.Entities:
Mesh:
Substances:
Year: 2017 PMID: 28905856 DOI: 10.1038/nrrheum.2017.140
Source DB: PubMed Journal: Nat Rev Rheumatol ISSN: 1759-4790 Impact factor: 20.543